Moderna R&D day: $1 billion in cost cuts, 10 product launches
Sep 12, 2024 · Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid...
Moderna reports surprise profit on higher-than-expected COVID …
6 days ago · MRNA. By Patrick Wingrove. (Reuters) -Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low ...
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand …
4 days ago · On Thursday, Moderna Inc. (NASDAQ:MRNA) reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 billion. The company attributed the growth to higher sales in the U.S ...
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View
5 days ago · MRNA. Moderna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a loss of $1.89 per share. In the year-ago period, management ...
News Details - Moderna
Mar 26, 2024 · In the NextCOVE (NCT05815498) Phase 3 pivotal trial, mRNA-1283 was shown to elicit a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2, compared to mRNA-1273.222.
News Details - Moderna
Mar 27, 2024 · Announces positive clinical trial data from three new vaccines against viruses that cause significant burden (Epstein-Barr virus, Varicella-Zoster virus, norovirus) and advances programs toward Phase 3 development. Anticipates U.S. launch of vaccine against RSV following FDA approval and ACIP recommendation in 2024.
News Details - Moderna
Sep 6, 2023 · Clinical trial data from research assay confirmed Moderna's updated COVID-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including BA.2.86, EG.5, and FL.1.5.1 variants
News Details - Moderna
Jan 8, 2024 · CAMBRIDGE, MA / ACCESSWIRE / January 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced business updates and progress on the Company's pipeline of transformative mRNA medicines. Moderna enters 2024 with 45 therapeutic and vaccine programs, nine of which are in late-stage development.
FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines …
FDA approved and authorized for emergency use updated mRNA COVID-19 vaccines (2024-2025 formula) to more closely target currently circulating variants to prevent COVID-19 and to provide better ...
Moderna’s stock pops after biotech ekes out a surprise profit, and ...
6 days ago · Moderna Inc.’s stock was higher but off its early highs Thursday, after the company’s third-quarter earnings showed an unexpected profit as well as revenue that beat estimates by a wide margin.